Astragaloside IV attenuates uremia-induced myocardial injury by inhibiting autophagy via ATF4.

ABSTRACT:

Background

Cardiovascular diseases (CVDs) are one of the primary causes of mortality in patients with uremia. The therapeutic value of intravenous Astragaloside (AS-IV) in the treatment of CVDs has been widely recognized. However, whether AS-IV treats CVDs complicated by uremia remains unknown. This study aimed to determine the effects and potential mechanisms of AS-IV in the treatment of CVDs associated with uremia.

Methods

The 5/6 nephrectomized mouse model and uremic serum (US)-induced myocardial injury model of H9C2 cells were established in this study. Various techniques, including echocardiography, ELISA, TUNEL assay, flow cytometry, Western blotting, immunofluorescence, transmission electron microscopy, and qRT-PCR, were employed to investigate the effects of AS-IV on

SUBMITTER: Xu J 

PROVIDER: S-EPMC12780190 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature